PAION AG: Invitation for a Converence Call

PAION Reports Positive Results of Its Short Acting Anaesthetic/Sedative Remimazolam (CNS 7056) in a Phase IIb Study in Colonoscopy

AACHEN, Germany--(BUSINESS WIRE)-- The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) will hold a conference call on Monday, 22nd November 2010 at 10.00 am CET for media representatives and shareholders in German.

PAION will also be available for analysts and investors in a conference call in English at 4.00 pm CET.

PAION will host the conference calls to present details on the headline data of the Phase IIb study with Remimazolam.

To access the call, please dial:

Germany +49 (0) 69 710445598
UK +44 (0) 20 3003 2666
US + 1 866 966 5335
(other countries: please choose from D/UK/US numbers).

The participant pass code is 'PAION'.

To allow for smooth processing we suggest that you dial in ten minutes before the beginning of the call.

The conference call will be supplemented by a webcast presentation which can be accessed during the call under the following link:

For the call at 10.00 am, please use the PIN 1961272.

For the call at 4.00 pm CET, please use the PIN 4349347.

The dial-in details for the conference call and the webcast link are also available on PAION's website

The conference call will be recorded. Details on how to access the replay will be posted on the same web page after the call.

About Remimazolam (CNS 7056)

Remimazolam is an innovative short-acting general anaesthetic/sedative. Sedatives are used, for example, in endoscopic procedures such as colonoscopies. After intravenous administration Remimazolam rapidly induces the desired sedation. Importantly, this sedative effect quickly disappears. This rapid offset of the effect of the substance is due to its metabolism by tissue esterase enzymes that are widely distributed throughout the body. Remimazolam is being developed as a sedative agent for day case procedures (procedural sedation) as well as for the induction and maintenance of anaesthesia. It could also be used as a sedative for patients in the Intensive Care Unit (ICU).

PAION is exploring partnering opportunities for the territories outside Japan, where the compound is partnered with Ono Pharmaceuticals in order to be able to initiate the development of Remimazolam in other indications as early as possible.

As recently published, the INN (International Nonproprietary Name) for CNS 7056 recommended by the World Health Organization is Remimazolam.


PAION is a biopharmaceutical company headquartered in Aachen, Germany and has a second site in Cambridge, UK. The company is specialized in developing and commercializing innovative drugs for the hospital-based treatment in indications for which there is a substantial unmet medical need. PAION has a 'Search & Develop' business model, which is based on its core expertise in drug development. Where appropriate, particularly during the late stages of the clinical development, PAION seeks to collaborate with experienced partners.


This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG's management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from the Company's assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update any such forward-looking statements to reflect future events or developments.

Language: English
Company: PAION AG
Martinstr. 10-12
52062 Aachen Deutschland
Phone: +49 (0)241-4453-0
Fax: +49 (0)241-4453-100
E-mail: [email protected]
ISIN: DE000A0B65S3
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Hamburg, München, Berlin, Düsseldorf, Stuttgart


Ralf Penner
Director Investor Relations / Public Relations
Martinstrasse 10-12
52062 Aachen - Germany
Phone: +49 241 4453-152
E-mail: [email protected]

KEYWORDS:   United Kingdom  United States  Europe  North America  Germany

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical